The Compassionate Use Advisory Committee (CompAC) for development of pre-approval access to investigational drugs. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract ...
Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when ...
Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive ...
A clinical pathway blends expertise from many providers. The primary goal of a clinical pathway is to produce maximum value at each practice site. Dr Konduri’s institution strongly emphasizes the ...
Treatment decision making and psychosocial outcomes associated with rapid genetic testing for BRCA1 and BRCA2 in women newly diagnosed with breast cancer. This is an ASCO Meeting Abstract from the ...
Nuvalent's stock has nearly doubled after positive phase 1 data from its second candidate, NVL-565, targeting ALK-positive NSCLC. The preliminary data showed early anti-tumor activity in heavily ...
In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback